Status:
COMPLETED
Suloexide in the Treatment of Early Stages of COVID-19
Lead Sponsor:
Clinedem
Collaborating Sponsors:
Alfasigma S.p.A.
Conditions:
Covid19
Eligibility:
All Genders
40-80 years
Phase:
PHASE2
PHASE3
Brief Summary
Problem: The COVID- 19 pandemic has not only affected our healthcare system, but the impact on the worldwide financial systems and our "normal" way of life is still to be determined. Although the pe...
Detailed Description
Objective: To use sulodexide in patients that have early onset of COVID-19 symptoms to mitigate the progression of the disease process that can allow them to recover at home, and limit the need for h...
Eligibility Criteria
Inclusion
- 3 days or less with clinical COVID-19 symptoms (fever, cough, sour throat, headache, body ache, anosmia, diarrhoea, vomiting).
- sign inform consent.
- \>50% risk developing a severe clinical presentation of COVID-19 according to risk calculator
Exclusion
- COVID-19 negative test
- known pregnancy
- chronic use of steroid medication
- deep vein thrombosis in the last 6 months
- extended anticoagulation in the last 3 months.
- known allergy to sulodexide.
- severe symptoms that warrant hospital care at initial screening
Key Trial Info
Start Date :
June 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 7 2020
Estimated Enrollment :
243 Patients enrolled
Trial Details
Trial ID
NCT04483830
Start Date
June 5 2020
End Date
September 7 2020
Last Update
September 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinedem
San Luis Río Colorado, Sonora, Mexico, 83449